Evidence map›Paper›PMID 41592682›Full record

ArticleJournal of advanced research2026

A novel extracellular vesicle-engineered immunotherapy drug for Her2

Xinliang Lu, Weiyi Yuan, Xianchang Zeng, Fanghui Zhang, Chengyan Zhang, Xinrong Li, Jufeng Guo, Jiayue Hao, Gensheng Zhang, Jianli Wang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xinliang LuDepartment of Hepatobiliary and Pancreatic Surgery, Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, China. Electronic address: xllu@zju.edu.cn.
Weiyi YuanLiangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang 311121, China.
Xianchang ZengDepartment of Hepatobiliary and Pancreatic Surgery, Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, China; Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang 311121, China.
Fanghui ZhangSchool of Medical Technology, Xinxiang Medical University, Xinxiang City 453003, Henan Province, China.
Chengyan ZhangDepartment of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 310016 Hangzhou, China.
Xinrong LiDepartment of Hepatobiliary and Pancreatic Surgery, Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, China.
Jufeng GuoDepartment of Breast Surgery, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang 310006, China.
Jiayue HaoDepartment of Hepatobiliary and Pancreatic Surgery, Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, China.
Gensheng ZhangDepartment of Critical Care Medicine of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China.
Jianli WangInstitute of Immunology and Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Hao WuDepartment of Gastroenterology, the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325000, China. Electronic address: walkerhao@126.com.
Zhijian CaiLiangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang 311121, China; Department of Orthopaedics of the Second Affiliated Hospital and Institute of Immunology, Zhejiang University School of Medicine, 310009 Hangzhou, China. Electronic address: caizj@zju.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trastuzumab profoundly improves outcomes of Her2

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesExtracellular VesiclesImmunotherapyAnimalsBrain NeoplasmsCD8-Positive T-LymphocytesCell Line, TumorChemokine CXCL9FemaleHumansMiceSingle-Chain AntibodiesTrastuzumabTumor MicroenvironmentChemokine CXCL9ERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesSingle-Chain AntibodiesTrastuzumabBrain metastatic tumorsCXCL9Extracellular vesiclesHer2Rabeprazole

Identifiers

PMID41592682
PMCPMC13669617

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.